Giorgio Iotti, PhD, is Head of Program Leadership and Control in the Rare Disease Unit in Chiesi Group. He is responsible for pipeline progression of all Biotech and Advanced Therapy programs.
He leads the Holoclar project, the first pharmaceutical product containing stem cells receiving marketing authorization in Europe, and other research and development programs for treatment of rare lysosomal storage disorders.
He has five years of experience as Medical Manager, with responsibility across various extremely innovative products such as Glybera and Holoclar.
Giorgio was a postdoctoral fellow at the FIRC Institute of Molecular Oncology in Milan, Italy, and Kimmel Cancer Center, Philadelphia, US. He received his PhD in Experimental Medicine from the University of Modena and Reggio Emilia, Italy. He published several peer-reviewed articles and abstracts in the area of molecular oncology and advanced therapies.